- In September 2024, Roche has expanded its digital pathology open environment by integrating over 20 AI algorithms from eight new partners to enhance cancer research and diagnosis. This initiative will support pathologists and scientists with advanced AI tools, positioning Roche to further innovate in the digital pathology space and strengthen its leadership in oncology diagnostics
- In September 2024, Lunit has partnered with Roche to integrate its Lunit SCOPE PD-L1 22C3 TPS into Roche's navify Digital Pathology platform, marking the first deployment of Lunit's AI technology with Roche. This collaboration will provide pathologists and scientists with advanced tools for cancer research, contributing to Roche’s digital pathology ecosystem. For Lunit, this partnership offers an opportunity to expand its AI technology in oncology and strengthen its presence in the global market
- In June 2024, Quest Diagnostics has completed its acquisition of PathAI Diagnostics to accelerate the adoption of AI and digital pathology in cancer and disease diagnosis. This acquisition will enhance Quest’s diagnostic capabilities, enabling more accurate and efficient disease detection through advanced AI technologies
- In February 2024, Roche has signed an agreement with PathAI to exclusively collaborate on developing AI-powered digital pathology algorithms for companion diagnostics through Roche Tissue Diagnostics. This partnership will strengthen Roche's position in the companion diagnostics market, enhancing its AI capabilities in pathology and accelerating innovation in personalized medicine
